SAFETY DATA SHEET



1. Identification

Product identifier Antirobe (Clindamycin Hydrochloride) Capsules - 75, 150, and 300 mg

Other means of identification

Synonyms Antirobe® * Antirobe Capsule * Antirobe Antibiotic Capsules * Clindamycin hydrochloride capsules

* Antirobe Antibiotic Capsules 75mg * Antirobe Antibiotic Capsules 150mg

Recommended useVeterinary product used as antibiotic agent

Recommended restrictions Not for human use **Manufacturer/Importer/Supplier/Distributor information**

Company Name (US) Zoetis Inc.

10 Sylvan Way

Parsippany, New Jersey 07054 (USA)

Rocky Mountain Poison

and Drug Center

1-866-531-8896

Product Support/Technical

Services

1-888-963-8471

Emergency telephone

numbers

CHEMTREC (24 hours): 1-800-424-9300

International CHEMTREC (24 hours): +1-703-527-3887

Company Name (EU) Zoetis Belgium S.A.

Rue Laid Burniat 1 1348 Louvain-la-Neuve

Belgium

Telephone: +32 10 808080

Emergency telephone

number

International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail VMIPSrecords@zoetis.com

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Serious eye damage/eye irritation Category 2A

Sensitization, skin Category 1

Environmental hazards Not classified.

OSHA defined hazards Not classified.

Label elements



Signal word Warning

Hazard statement Causes serious eye irritation. May cause an allergic skin reaction.

Precautionary statement

Prevention Avoid breathing dust/fume/gas/mist/vapors/spray. Wash thoroughly after handling. Contaminated

work clothing must not be allowed out of the workplace. Wear eye protection/face protection.

Wear protective gloves.

Response If on skin: Wash with plenty of water. If skin irritation or rash occurs: Get medical advice/attention.

Wash contaminated clothing before reuse. If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation

persists: Get medical advice/attention.

Storage Store away from incompatible materials.

Disposal Dispose of contents/container in accordance with local/regional/national/international regulations.

Hazard(s) not otherwise classified (HNOC)

None known.

Supplemental information

May cause effects similar to those generally seen in clinical use of antibiotics including gastrointestinal irritation, vomiting, transient diarrhea, nausea, and abdominal pain.

Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps,

low-grade fever, bloody stools, and abdominal pain) may also occur.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
Clindamycin Hydrochloride		#	29.4 - 56
Talc (non-asbestiform)		14807-96-6	*

Composition comments

#: CAS 21462-39-5 or CAS 58207-19-5

* In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has

been withheld as a trade secret.

4. First-aid measures

Inhalation

Move to fresh air. Call a physician if symptoms develop or persist. For breathing difficulties, oxygen

may be necessary.

Skin contact

Remove contaminated clothing immediately and wash skin with soap and water. In case of eczema or other skin disorders: Seek medical attention and take along these instructions.

Eye contact

Immediately flush eyes with plenty of water for at least 15 minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Get medical attention if irritation develops and persists.

Rinse mouth. Call a physician or poison control center immediately. Only induce vomiting at the instruction of medical personnel. Never give anything by mouth to an unconscious person.

Most important

symptoms/effects, acute and

delayed

Ingestion

Causes serious eye irritation. Symptoms may include stinging, tearing, redness, swelling, and blurred vision. May cause an allergic skin reaction. Dermatitis. Rash. Ingestion may result in mild gastrointestinal irritation with nausea, vomiting, or diarrhea.

Indication of immediate medical attention and special treatment needed

Provide general supportive measures and treat symptomatically. Keep victim under observation.

Symptoms may be delayed.

General information

For personal protection, see section 8 of the SDS. Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. Wash contaminated clothing before reuse.

5. Fire-fighting measures

Suitable extinguishing media

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2). Apply extinguishing media

carefully to avoid creating airborne dust.

Unsuitable extinguishing media

Do not use water jet as an extinguisher, as this will spread the fire.

Specific hazards arising from the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for firefighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting equipment/instructions

Use water spray to cool unopened containers.

Specific methods

Use standard firefighting procedures and consider the hazards of other involved materials.

General fire hazards

During processing, dust may form explosive mixture in air. Fine particles (such as mists) may fuel

fires/explosions.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

Keep unnecessary personnel away. Ensure adequate ventilation. ELIMINATE all ignition sources (no smoking, flares, sparks or flames in immediate area). Avoid dust formation. Ventilate the contaminated area. Wear appropriate protective equipment and clothing during clean-up. Do not breathe dust. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up

Avoid contact with eyes, skin, and clothing. For waste disposal, see section 13 of the SDS. Ensure adequate ventilation. Avoid dust formation. Eliminate all ignition sources (no smoking, flares, sparks, or flames in immediate area). Prevent product from entering drains.

Large Spills: Stop the flow of material, if this is without risk. Ground/bond container and equipment. Sweep up or vacuum up spillage and collect in suitable container for disposal. Clean contaminated surface thoroughly. Prevent release to the environment.

Small Spills: Wipe up with a damp cloth and place in container for disposal. Clean surface thoroughly to remove residual contamination.

Never return spills to original containers for re-use.

Environmental precautions

Avoid release to the environment. Inform appropriate managerial or supervisory personnel of all environmental releases. Prevent further leakage or spillage if safe to do so. Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling

Wear personal protective equipment. Avoid contact with skin. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes. When using, do not eat, drink or smoke. Wash thoroughly after handling. Wash contaminated clothing before reuse. Do not handle, store or open near an open flame, sources of heat or sources of ignition. Protect material from direct sunlight. Avoid release to the environment. Observe good industrial hygiene practices.

Conditions for safe storage, including any incompatibilities

Use care in handling/storage. Store in a well-ventilated place. @ 15-30°C (59-86°F).. Protect from sunlight. Keep away from heat, sparks and open flame. Keep away from food, drink and animal feedingstuffs. Keep out of the reach of children. Store away from incompatible materials (see Section 10 of the SDS).

8. Exposure controls/personal protection

Occupational exposure limits

The following constituents are the only constituents of the product which have a PEL, TLV or other recommended exposure limit. At this time, the other constituents have no known exposure limits.

Zoetis			
Components	Туре	Value	
Clindamycin Hydrochloride	TWA	100 μg/m³	
US. OSHA Table Z-3 (29 CFR 191	0.1000)		
Components	Туре	Value	Form
Talc (non-asbestiform) (CAS 14807-96-6)	TWA	0.1 mg/m3	Respirable.
		20 mppcf	
		2.4 mppcf	Respirable.
US. ACGIH Threshold Limit Valu	es		
Components	Туре	Value	Form
Talc (non-asbestiform) (CAS 14807-96-6)	TWA	2 mg/m3	Respirable fraction.
US. NIOSH: Pocket Guide to Che	mical Hazards		
Components	Туре	Value	Form
Talc (non-asbestiform) (CAS 14807-96-6)	TWA	2 mg/m3	Respirable.

Biological limit values

No biological exposure limits noted for the ingredient(s).

Control banding approach

Not available.

Appropriate engineering

controls

Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level.

General ventilation normally adequate.

Individual protection measures, such as personal protective equipment

Eye/face protection If contact is likely, safety glasses with side shields are recommended.

Skin protection

Hand protection Wear protective gloves.

Other Wear suitable protective clothing. Use protective clothing (uniforms, lab coats, disposable

coveralls, etc.) in both production and laboratory areas.

Respiratory protection No personal respiratory protective equipment normally required. If engineering controls do not

> maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (in countries where exposure limits have not been established), an approved respirator must be worn. Respiratory protection should be provided in instances where exposure to

dust, mists, aerosols or vapors are likely.

Thermal hazards Not applicable.

General hygiene considerations

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. Contaminated work clothing should not be allowed out of the workplace.

9. Physical and chemical properties

Capsule **Appearance** Solid. Physical state Solid. **Form**

75 mg - Green, 150 mg - Light blue and green (or blue and white), 300 mg - Blue Color

Odor Not available. Not available. **Odor threshold** Not available. Not available. Melting point/freezing point Not available. Initial boiling point and boiling

range

Flash point Not available. **Evaporation rate** Not available. Not available. Flammability (solid, gas) Upper/lower flammability or explosive limits Explosive limit - lower (%) Not available.

Explosive limit - upper (%) Not available. Vapor pressure Not available. Vapor density Not available. Not available. Relative density

Solubility(ies)

Not available. Solubility (water) Partition coefficient Not available. (n-octanol/water)

Not available. **Auto-ignition temperature Decomposition temperature** Not available. Not available. Viscosity

Other information

Not explosive. **Explosive properties** Oxidizing properties Not oxidizing.

10. Stability and reactivity

Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid Heat, flames and sparks. Contact with incompatible materials. Protect from sunlight. Avoid

dispersion as a dust cloud.

Incompatible materials Strong oxidizing agents.

Hazardous decomposition

products

hydrogen chloride.

Material name: Antirobe (Clindamycin Hydrochloride) Capsules - 75, 150, and 300 mg SDS US Version #: 06 Revision date: 04-28-2022 Issue date: 10-28-2013

Thermal decomposition products may include oxides of carbon, nitrogen, and sulfur. May include

11. Toxicological information

Information on likely routes of exposure

Inhalation Under normal conditions of intended use, this material is not expected to be an

inhalation hazard.

Skin contact May cause an allergic skin reaction.

Clindamycin Hydrochloride Species: Rat

Severity: No effect

Eye contact Causes serious eye irritation.

Clindamycin Hydrochloride Species: Rabbit

Severity: Moderate

Species: Rat Severity: No effect

Ingestion May cause discomfort if swallowed.

Symptoms related to the physical, chemical and toxicological characteristics

Causes serious eye irritation. Symptoms may include stinging, tearing, redness, swelling, and blurred vision. May cause an allergic skin reaction. Dermatitis. Rash. Ingestion may result in mild gastrointestinal irritation with nausea, vomiting, or diarrhea.

Information on toxicological effects

Acute toxicity May cause an allergic skin reaction.

Components Species Test Results

Clindamycin Hydrochloride

Acute

Intravenous

LD50 Mouse 143 mg/kg

Oral

LD50 Mouse 1479 mg/kg

Rat 2618 mg/kg

Other

LD50 Rat 279 mg/kg [Sub-tenon injection (eye)]

Subcutaneous

LD50 Rat 891 mg/kg

Chronic

Oral

LOAEL Dog 600 mg/kg/day, 6 months [Target organ:

Gastrointestinal system]

NOAEL Rat 600 mg/kg/day, 6 months [No effects at

maximum dose]

300 mg/kg/day, 1 years [No effects at

maximum dose]

<u>Subacute</u>

Oral

NOAEL Dog 300 mg/kg/day, 1 months [No effects at

maximum dose]

Talc (non-asbestiform) (CAS 14807-96-6)

<u>Acute</u>

Oral

LD50 Rat > 1600 mg/kg

Skin corrosion/irritation Prolonged skin contact may cause temporary irritation.

Corrosivity

Clindamycin Hydrochloride Species: Rat

Severity: No effect

Serious eye damage/eye

irritation

Causes serious eye irritation.

Eye Contact

Clindamycin Hydrochloride

Species: Rabbit Severity: Moderate

Species: Rat Severity: No effect

Respiratory or skin sensitization

Respiratory sensitization Not a respiratory sensitizer.

May cause an allergic skin reaction. Skin sensitization

No data available to indicate product or any components present at greater than 0.1% are Germ cell mutagenicity

mutagenic or genotoxic.

Mutagenicity

Clindamycin Hydrochloride Bacterial Mutagenicity (Ames)

> Result: Negative Species: Salmonella

In Vitro Micronucleus Result: Negative

Carcinogenicity Based on available data, the classification criteria are not met, Industrial use -

Inhalation: Not classifiable as to carcinogenicity to humans.

IARC Monographs. Overall Evaluation of Carcinogenicity

Talc (non-asbestiform) (CAS 14807-96-6) 2B Possibly carcinogenic to humans.

3 Not classifiable as to carcinogenicity to humans.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

Not listed

US. National Toxicology Program (NTP) Report on Carcinogens

Not listed.

This product is not expected to cause reproductive or developmental effects. Based on available Reproductive toxicity

data, the classification criteria are not met.

Developmental effects

Clindamycin Hydrochloride 250 mg/kg/day Embryo / Fetal Development, Not Teratogenic

> Result: NOAEL Species: Rat

Organ: Subcutaneous

600 mg/kg/day Embryo / Fetal Development, Not Teratogenic

Result: NOAEL Species: Mouse Organ: Oral

600 mg/kg/day Embryo / Fetal Development, Not Teratogenic

Result: NOAEL Species: Rat Organ: Oral

Reproductivity

Clindamycin Hydrochloride 300 mg/kg/day Reproductive & Fertility, Fertility

> Result: NOAEL Species: Rat Organ: Oral

Specific target organ toxicity -

single exposure

Not classified.

Specific target organ toxicity -

repeated exposure

Due to partial or complete lack of data the classification is not possible. This product may affect Blood. Gastrointestinal tract. Liver. through prolonged or repeated exposure.

Aspiration hazard Not an aspiration hazard.

Chronic effects Prolonged inhalation may be harmful. Prolonged exposure may cause chronic effects.

Individuals sensitive to this material or other materials in its chemical class may develop **Further information**

allergic reactions. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, and abdominal pain) may

also occur.

12. Ecological information

Ecotoxicity The product is not classified as environmentally hazardous. However, this does not exclude the

possibility that large or frequent spills can have a harmful or damaging effect on the environment.

Avoid release to the environment.

Persistence and degradability No data is available on the degradability of this product.

No data available. Bioaccumulative potential No data available. Mobility in soil

Other adverse effects No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation

potential, endocrine disruption, global warming potential) are expected from this component.

13. Disposal considerations

Disposal instructions Avoid release to the environment. Considering the relevant known environmental and human

health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. Dispose of contents/container in accordance with local/regional/national/international

regulations.

Dispose in accordance with all applicable regulations. Local disposal regulations

Hazardous waste code None known.

Waste from residues / unused

products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner.

Since emptied containers may retain product residue, follow label warnings even after container is Contaminated packaging

emptied.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and Not applicable.

the IBC Code

15. Regulatory information

This product is a "Hazardous Chemical" as defined by the OSHA Hazard Communication US federal regulations

Standard, 29 CFR 1910.1200.

Toxic Substances Control Act (TSCA)

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

Superfund Amendments and Reauthorization Act of 1986 (SARA)

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous Yes

chemical

Classified hazard
categoriesSerious eye damage or eye irritation
Respiratory or skin sensitization

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act

(SDWA)

Not regulated.

US state regulations California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material

is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

US. California. Candidate Chemicals List. Safer Consumer Products Regulations (Cal. Code Regs, tit. 22, 69502.3, subd. (a))

Talc (non-asbestiform) (CAS 14807-96-6)

California Proposition 65

California Proposition 65 - CRT: Listed date/Carcinogenic substance

Inventory name

Talc (non-asbestiform) (CAS 14807-96-6) Listed: April 1, 1990

International Inventories

Country(s) or region

ocana y (o) or region	inventory name	
Australia	Australian Inventory of Industrial Chemicals (AICIS)	No
Canada	Domestic Substances List (DSL)	Yes
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	Yes
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	Yes
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	Yes
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	Yes
Taiwan	Taiwan Chemical Substance Inventory (TCSI)	Yes
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

 Issue date
 10-28-2013

 Revision date
 04-28-2022

Version # 06

DisclaimerZoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while

it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time. The information in the sheet was written based on the best knowledge and experience currently

available.

Revision informationThis document has undergone significant changes and should be reviewed in its entirety.

Material name: Antirobe (Clindamycin Hydrochloride) Capsules - 75, 150, and 300 mg Version #: 06 Revision date: 04-28-2022 Issue date: 10-28-2013 On inventory (yes/no)*